Ofichem acquires Avivia B.V. to expand formulation development capabilities

Nijmegen, Netherlands, Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a company specialized in formulation development based in Nijmegen, the Netherlands. The acquisition marks a significant step in Ofichem’s strategy to become a fully integrated provider of development solutions across drug substance and drug product, with a focus on complex formulations.

Avivia is a Contract Development Organization (CDO) with extensive expertise in formulation development, analytical method development, dissolution testing, and excipient characterization. The acquisition will strengthen Ofichem’s integrated development offering, enabling the group to offer broader, deeper support from early-phase development through to GMP production.

“By integrating Avivia into the Ofichem Group, we are strengthening our ability to support customers from drug substance through R&D and small to large scale GMP manufacturing and reinforcing our commitment to innovation and customer-centricity,” said Dr. Weite H. Oldenziel, CEO and owner of the Ofichem Group. “This acquisition complements our capabilities in Ter Apel and Leiden and enables us to offer broader, more integrated services to our global customers.”

The company’s team of 10 specialised professionals brings more than 25 years’ experience and a strong track record in solving complex development challenges.

“This move further supports our ambition to evolve as a science-led CDMO and deliver innovation-driven solutions to our customers with enhanced capability in solving complex formulation challenges,” Weite added. “We’re excited to welcome Avivia’s talented team into the Ofichem Group.”

“We’re absolutely delighted to be joining the Ofichem family,” said Dennie van den Heuvel, Development Director at Avivia. “This is an exciting step forward for us, one that opens the door to enhanced service offerings for our customers. We remain deeply committed to delivering high-quality formulation development services, and this new chapter strengthens our ability to do just that, with even greater reach and expertise.”

The acquisition aligns with Ofichem’s broader M&A agenda and ongoing investment strategy. The company is actively exploring additional opportunities to strengthen capabilities in both Europe and North America, with a focus on innovative technologies and early-phase development services.

About Ofichem
Ofichem is a European-centred CDMO trusted by pharma and compounding customers with responsive, reliable solutions across APIs and drug products. With over 50 years of regulatory expertise and GMP-certified operations, Ofichem delivers flexible, audit-ready services tailored to client needs, from small batches to larger-scale supply. Known for clarity, speed, and a no-nonsense approach, the company combines technical excellence with a partnership mindset. Ofichem brings the experience to guide and the commitment to stand by its clients, building strong relationships that last.

About Avivia B.V.
Avivia is a formulation development company located in Nijmegen, the Netherlands. It supports pharmaceutical clients within formulation and pharmaceutical development, with a focus on formulation development, analytical method development, dissolution testing, and excipient characterization aimed at improving patient outcomes. Avivia’s team is known for its scientific expertise and solution-oriented approach.

Media contact
Aranda Rahbarkouhi
ramarketing
aranda@ramarketingpr.com